United States Laboratory Disposable Products Market By Product (Specimen Containers, Transport Vials, Collection & Transport Swabs, Tissue Collectors, and Optical Grade), By Material (Glass and Plastic), By End Use (Hospitals, Ambulatory Surgical Centers, CROs, and Others), By Region, Competition, Forecast & Opportunities, 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 1.45 BIllion
CAGR (2026-2031)	7.91%
Fastest Growing Segment	Specimen Containers
Largest Market	West
Market Size (2031)	USD 2.29 BIllion

Market Overview

The United States Laboratory Disposable Products Market will grow from USD 1.45 BIllion in 2025 to USD 2.29 BIllion by 2031 at a 7.91% CAGR. Laboratory disposable products comprise single-use consumables such as test tubes, pipettes, petri dishes, and personal protective equipment that are essential for maintaining sterility and preventing cross-contamination in clinical and research environments. The primary drivers supporting the growth of this market include the rising prevalence of chronic diseases which necessitates frequent diagnostic monitoring and the continuous expansion of pharmaceutical research and development. Additionally, a sustained focus on infectious disease surveillance and prevention has permanently elevated the baseline demand for testing supplies across the healthcare infrastructure.

According to the American Clinical Laboratory Association, in 2024, the clinical laboratory sector contributed over $118 billion to the national economic output, a figure that underscores the massive operational scale driving the consumption of these essential daily supplies. Despite this robust demand, the market encounters a significant challenge regarding the environmental impact of plastic waste generated by high volumes of single-use items. Increasing regulatory pressure to manage biomedical waste and the rising costs associated with sustainable disposal methods could continually impede the rapid expansion of the market.

Key Market Drivers

The Expansion of Pharmaceutical and Biotechnology Research and Development Activities is a primary catalyst propelling the demand for laboratory disposable products. As drug discovery becomes increasingly complex, biopharmaceutical companies are heavily investing in preclinical and clinical trials that rely on a vast array of single-use consumables, including pipettes and reagent reservoirs, to ensure data integrity. This surge in investigative intensity is reflected in the sector's substantial financial commitment. According to the Pharmaceutical Research and Manufacturers of America (PhRMA), in its 2024 Special 301 Submission, member companies invested nearly $101 billion in research and development in 2022 to facilitate new treatments. This funding level directly correlates with higher procurement rates for disposable supplies essential for maintaining sterile workflows in high-throughput screening processes.

Simultaneously, the Rising Prevalence of Chronic and Infectious Diseases Requiring Diagnostic Testing is reshaping the market by sustaining high-volume demand for specimen collection tools. The escalating burden of long-term conditions necessitates frequent monitoring, thereby increasing the consumption of test tubes and collection vials. According to the American Cancer Society, January 2024, in the 'Cancer Facts & Figures 2024' report, the projected number of new cancer diagnoses in the United States was expected to top 2 million for the first time in 2024. This growing patient pool compels diagnostic providers to scale operations significantly. Illustrating this operational scale, according to Labcorp, in February 2024, the company performed more than 600 million tests globally in 2023, highlighting the critical reliance on disposables to execute diagnostic procedures.

Download Free Sample Report

Key Market Challenges

The sustained expansion of the United States Laboratory Disposable Products Market is significantly hindered by the escalating environmental burden associated with single-use plastic waste. As clinical and research facilities continue to generate vast quantities of non-biodegradable refuse, they face intensifying scrutiny from environmental regulators and sustainability advocates. This pressure forces laboratories to adopt more expensive waste management protocols, which directly increases operational overhead and constrains budgets that would otherwise fund market procurement. The reliance on single-use items, while necessary for sterility, creates a linear consumption model that is increasingly viewed as financially and ecologically unsustainable.

According to Practice Greenhealth, in 2024, United States health care facilities generated approximately 14,000 tons of waste daily, with 20% to 25% of this volume consisting of plastics. This substantial accumulation of plastic debris compels facilities to divert resources toward costly disposal and recycling initiatives rather than expanding their inventory of disposable products. Consequently, the rising financial and logistical costs of managing this waste stream continually dampen the market's potential for rapid economic growth.

Key Market Trends

The Adoption of Sustainable and Biodegradable Laboratory Plastics is rapidly gaining momentum as research institutions prioritize circular economy principles. Laboratories are increasingly shifting procurement toward eco-labeled consumables and bio-based polymers, driven by stringent sustainability mandates. This transition is formalized through third-party frameworks that validate the integration of green products into daily workflows. According to My Green Lab, January 2025, in its 'A Year of Progress' report, the certification program expanded to include over 3,750 labs globally in 2024, underscoring the growing operational reliance on sustainable disposable supplies.

The Adoption of Sterile Single-Use Products for Bioprocessing is reshaping the manufacturing landscape for biologics and advanced therapies. Biopharmaceutical companies are replacing stainless-steel equipment with disposable fluid path technologies, such as single-use bags and mixers, to eliminate cleaning validation and accelerate batch turnover. This trend addresses the flexibility required in large-scale production environments. According to Sartorius, January 2025, in its 'Fiscal 2024 Preliminary Results', the Bioprocess Solutions division reported an order intake increase of 12.7 percent, a recovery significantly driven by the renewed uptake of these essential single-use consumables.

Segmental Insights

The specimen containers segment represents the fastest-growing category within the United States Laboratory Disposable Products Market, driven by the escalating volume of diagnostic screenings and sample collection activities. This rapid expansion is largely attributed to stringent infection control protocols reinforced by the U.S. Food and Drug Administration, which necessitate the use of sterile, single-use vessels to prevent cross-contamination during transport and analysis. Additionally, the heightened focus on early disease detection and chronic management has significantly increased the daily consumption of these essential consumables in clinical laboratories nationwide.

Regional Insights

The West United States maintains a leading position in the laboratory disposable products market due to a dense concentration of biopharmaceutical companies and advanced research institutions. This region, particularly California, hosts major biotechnology hubs that generate substantial demand for single-use laboratory supplies through extensive research and development initiatives. Additionally, the presence of prominent academic centers and frequent clinical trial activities ensures a steady requirement for diverse disposable products. This robust ecosystem of commercial and academic research directly supports the sustained market dominance of the Western region.

Recent Developments

• In October 2024, Avantor, Inc. expanded its strategic partnership with the National Institute for Bioprocessing Research and Training to address critical challenges in biopharmaceutical manufacturing. The collaboration focused on optimizing downstream processing for monoclonal antibodies by deploying the company’s advanced aseptic fluid handling technologies, including single-use systems and pump platforms. This initiative aimed to create realistic training environments that replicate industrial workflows, thereby helping the workforce overcome manufacturing bottlenecks. By integrating these disposable solutions into educational programs, the company sought to enhance production efficiency and support the rapid delivery of new therapies to the market.
• In September 2024, Becton, Dickinson and Company announced the commercial release of a new glass prefillable syringe specifically engineered for the delivery of high-viscosity biologic therapies. The product, marketed as the BD Neopak XtraFlow, was developed to eliminate design constraints often associated with complex drug formulations, offering a robust solution for subcutaneous administration. Alongside this product launch, the company confirmed an expansion of its manufacturing capacity to support the increasing global demand for biologic drug delivery systems. This development underscored the company's commitment to advancing its portfolio of disposable medical and laboratory devices to improve patient outcomes.
• In September 2024, DWK Life Sciences unveiled a comprehensive portfolio of enhanced pharmaceutical packaging and laboratory solutions at the CPHI trade show. The newly introduced products included ready-to-use (RTU) packaging formats, specialized bottles for biopharmaceutical production, and a wide array of injectable and diagnostic vials accompanied by sealing components. These disposable items were designed to facilitate scalability from the drug discovery phase through to final manufacturing, ensuring high standards of product integrity and safety. This launch highlighted the company's focus on supporting the pharmaceutical workflow with reliable, high-quality glass and plastic consumables.
• In July 2024, Eppendorf SE introduced a sustainable line of laboratory consumables manufactured from recycled polypropylene to address the environmental footprint of life science research. The company began utilizing post-consumer recyclates, derived from industrial residues such as those from contact lens production, to manufacture racks for single-use pipette tips. This transition aimed to significantly reduce carbon dioxide emissions while maintaining the high purity and sterility standards required for precise laboratory applications. The initiative represented a significant step in the company's strategy to replace fossil-based plastics with renewable or recycled materials across its range of disposable lab products.

Key Market Players

• Cardinal Health, Inc.
• Thomas Scientific LLC
• Medicus Health
• Avantor, Inc.
• Dynarex Corporation
• Thermo Fisher Scientific Inc.
• Mckesson Corporation
• Medline Industries, Inc.
• Becton, Dickinson and Company
• Agilent Technologies, Inc.

By Product	By Material	By End Use	By Region
Specimen Containers Transport Vials Collection & Transport Swabs Tissue Collectors Optical Grade	Glass Plastic	Hospitals Ambulatory Surgical Centers CROs Others	Northeast Midwest South West

Report Scope:

In this report, the United States Laboratory Disposable Products Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• United States Laboratory Disposable Products Market, By Product:

• Specimen Containers
• Transport Vials
• Collection & Transport Swabs
• Tissue Collectors
• Optical Grade

• United States Laboratory Disposable Products Market, By Material:

• Glass
• Plastic

• United States Laboratory Disposable Products Market, By End Use:

• Hospitals
• Ambulatory Surgical Centers
• CROs
• Others

• United States Laboratory Disposable Products Market, By Region:

• Northeast
• Midwest
• South
• West